Half a year after the FDA snatched back an approval for TG Therapeutics’ first-in-class lymphoma med Ukoniq, the company has landed a regulatory win. Wednesday, TG snared U.S. approval for its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback